10:56 AM EST, 02/28/2025 (MT Newswires) -- Moderna ( MRNA ) said Friday it has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency for mRESVIA, its respiratory syncytial virus vaccine for adults 60 and over.

RSV is a highly contagious seasonal virus that causes lower respiratory tract infections and pneumonia, the company said.

The approval is based on the phase 3 ConquerRSV trial, which included around 37,000 adults aged 60 and older across 22 countries, the company said, adding that the trial found no serious safety concerns.

MRNA shares were 0.6% higher in recent trading.

Price: 31.28, Change: +0.19, Percent Change: +0.61